Prior to issuing a registration under 21 U.S.C. 952(a) (2) (B), and in accordance with 21 CFR 1301.34 (a), this is notice that on July 20, 2007, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, TX 78664, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule I and II:
|Gamma hydroxybutyric acid (2010)||I|
|Lysergic acid diethylamide (7315)||I|
|Etorphine (except HCI)(9056)||I|
|Dextropropoxyphene, bulk (non-dosage forms) (9273)||II|
|Poppy Straw Concentrate (9670)||II|
The company plans to import small quantities of the listed controlled substances for the manufacture of analytical reference standards.
Any bulk manufacturers who are presently, or are applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC. 20537; or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 26, 2007.
This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.Start Signature
Dated: August 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E7-16862 Filed 8-24-07; 8:45 am]
BILLING CODE 4410-09-P